Ciprofloxacin GMP is Ciprofloxacin (HY-B0356) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 85721-33-1
- Formule: C17H18FN3O3
- Masse moléculaire:331.34
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Topoisomerase
More
Activité biologique
Ciprofloxacin (GMP) (2.5-10 μg/mL; 24-72 h) preserves the stem cell-like spindle morphology of immortalized human dermal papilla cells, and concentrations of 5 and 10 μg/mL for 72 h significantly increase cell aggregation size and number[1].
Ciprofloxacin (GMP) (10 μg/mL; 72 h) preserves CD133 stem cell marker expression and prevents increased procollagen type I fibroblast marker expression in immortalized human dermal papilla cells[1].
Ciprofloxacin (GMP) (10 μg/mL; 24-72 h) prevents time-dependent loss of CD133, integrin β1, and ALDH1A1 stem cell markers and increases in procollagen type I fibroblast marker in immortalized human dermal papilla cells; concentrations of 2.5-10 μg/mL for 72 h modulate these markers in a dose-dependent manner[1].
Ciprofloxacin (GMP) (2.5-10 μg/mL; 72 h) activates the Akt/GSK3β/β-catenin pathway in immortalized human dermal papilla cells in vitro in a dose-dependent manner, increasing activated Akt, inactivated GSK3β, and β-catenin levels[1].
Ciprofloxacin (GMP) (2.5-10 μg/mL; 72 h) activates the Akt/GSK3β/β-catenin pathway and upregulates EMT transcription factors (ZEB1, Snail) in primary human dermal papilla cells in vitro in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:immortalized human dermal papilla cells (DPCs)
-
Concentration:2.5-10 μg/mL
-
Incubation Time:72 h
-
Result:Increased levels of phosphorylated (activated) Akt (Ser 473), phosphorylated (inactivated) GSK3β (Ser 9), and β-catenin in a dose-dependent manner, with total Akt and GSK3β levels unchanged.\nSignificantly upregulated ZEB1, Snail, N-cadherin, vimentin, phosphorylated Erk (Thr 202/Tyr 204), Nanog, and Oct-4 in a dose-dependent manner, with minimal change in Slug levels.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (SD) (male, 4-week-old, drug-induced knee joint articular cartilage damage)[2]
-
Dosage:400 mg/kg; 800 mg/kg; 1200 mg/kg
-
Administration:i.g.; daily; 7 days
-
Result:Showed no obvious cartilage alterations at 400 mg/kg.
Caused severe cartilage lesions including matrix swelling and chondrocyte loss, and significantly decreased femoral condyle cartilage thickness compared to controls at 800 mg/kg or 1200 mg/kg.
Produced a maximum serum concentration (Cmax) of 9.6 mg/L, area under the plasma concentration-time curve (AUC0-∞) of 48.1 mg·h·L-1, and cartilage concentration of 7.4 μg·g-1 at 400 mg/kg on day 1.
Produced a Cmax of 16.3 mg/L, AUC0-∞ of 97.2 mg·h·L-1, and cartilage concentration of 13.4 μg·g-1 at 800 mg/kg on day 1.
Produced a Cmax of 21.8 mg/L, AUC0-∞ of 143.1 mg·h·L-1, and cartilage concentration of 20.3 μg·g-1 at 1200 mg/kg on day 1.
Produced a Cmax of 9.4 mg/L and AUC0-∞ of 51.1 mg·h·L-1 at 400 mg/kg on day 6.
Produced a Cmax of 15.2 mg/L and AUC0-∞ of 95.4 mg·h·L-1 at 800 mg/kg on day 6.
Produced a Cmax of 23.7 mg/L and AUC0-∞ of 148.8 mg·h·L-1 at 1200 mg/kg on day 6.
Demonstrated similar Cmax and AUC0-∞ values on day 1 and day 6, indicating no drug accumulation with repeated dosing.
Chemical Information
-
CAS No. 85721-33-1
-
Masse moléculaire 331.34
-
Formule C17H18FN3O3
-
SMILES
O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O
-
Synonyms
Bay-09867 (GMP)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Kiratipaiboon C, et al. Ciprofloxacin Improves the Stemness of Human Dermal Papilla Cells. Stem Cells Int. 2016;2016:5831276. [Content Brief]
[3]. Kamocki K, et al. Effects of ciprofloxacin-containing antimicrobial scaffolds on dental pulp stem cell viability-In vitro studies. Arch Oral Biol. 2015;60(8):1131-1137. [Content Brief]
[4]. Ilgin S, et al. Ciprofloxacin-induced neurotoxicity: evaluation of possible underlying mechanisms. Toxicol Mech Methods. 2015;25(5):374-381. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ciprofloxacin (GMP) Related Classifications
HY-B0356G Related Classifications
Powered by Bioz